Pulmonary Hypertension Associated with Use of Phentermine

Woo-Dae Bang; Ji-Ye Kim; Hee-Tae Yu; Sung-Soo Cho; Ji-Yong Jang; Chang-Myung Oh; Boyoung Joung; Hyuk-Jae Chang
November 2010
Yonsei Medical Journal;11/1/2010, Vol. 51 Issue 6, p971
Academic Journal
Weight-control drugs (known as anorexigens) such as fenfluramine have been linked with pulmonary hypertension in previous reports. In our case, a 29 year old woman was admitted for shortness of breath and was diagnosed with pulmonary hypertension. Three months ago, she had been taking phentermine for five weeks. Other factors that might have contributed to the development of pulmonary hypertension were excluded. With treatment, her symptoms improved. This is the first case that can suggest a possible connection between phenermine single medication with pulmonary hypertension. Phentermine has been considered a relatively safe drug to treat obesity, and further investigation is needed to decide the safety and dosage of phentermine.


Related Articles

  • New research aims to assess Redux/phen-fen controversy. Shaw, Kendall // Drug Store News;12/14/98, Vol. 20 Issue 20, pCP23 

    Reports on the results of a study on the physiological effects of Redux or phentermine-fenfluramine intake. Average duration of Redux therapy; Rates of mild or greater aortic regurgitation; Mitral valve regurgitation; Cardiovascular symptoms; Aortic regurgitation.

  • Diet pills--out with the old, in with the new.  // Consumers' Research Magazine;Nov97, Vol. 80 Issue 11, p40 

    Introduces the fenfluramine and phentermine diet drugs for weight loss endorsed by Eli Lily and Dupont Merck. Advantages of the drug.

  • Amfepramone: new cases of primary pulmonary hypertension.  // WHO Drug Information;2001, Vol. 15 Issue 1, p24 

    Reports cases of primary pulmonary hypertension (PPH) associated with previous use of amfepramone with or without fenfluramine or phentermine in Belgium. Identification of the risk factors of PPH; Prolongation of the re-authorization of amfepramone; Re-assessment of amfepramone.

  • Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension Blanpain, C├ędric; Le Poul, Emmanuel; Parma, Jasmine; Knoop, Christiane; Detheux, Michel; Parmentier, Marc; Vassart, Gilbert; Abramowicz, Marc J. // Cardiovascular Research;Dec2003, Vol. 60 Issue 3, p518 

    Objective: Appetite-suppressant drug fenfluramine is implicated in primary pulmonary hypertension (PPH) but the molecular pathways that mediate this effect are unknown. A mouse model incriminates the serotonin 5-HT2B receptor but contrasts with other models where this receptor has been shown to...

  • Can diet pills damage my heart? Griffin, Katherine; Franklin, Deborah // Health (Time Inc. Health);Oct97, Vol. 11 Issue 7, p20 

    Presents an overview of the possible effects of diet pills on the health of individuals. Results of the studies done on Mayo Clinic and MeritCare Medical Center; Individual and collective effects of flenfluramine and phentermine to health; Statistics of diet pills victims; Medical advice given...

  • Pharmacologic Induction of Weight Loss to Treat Type 2 Diabetes. Redmon, J. Bruce; Raatz, Susan K.; Kwong, Christine A.; Swanson, Joyce E.; Thomas, William; Bantle, John P. // Diabetes Care;Jun99, Vol. 22 Issue 6, p896 

    Presents a study which conducted a placebo-controlled trial of the weight-loss medications fenfluramine and phentermine in type 2 diabetic subjects. Research design and methods; Results; Conclusions.

  • The demise of diet pills. Napier, Kristine // Prevention;Dec97, Vol. 49 Issue 12, p40 

    Looks at the demise of diet pills as of November 1997. The reported cases of rare heart-valve disease in women who took the weight-loss combo fen-phen (fenfluramine and phentermine) in July 1997; The side effects of Redux; The voluntary removal of both drugs from the market in September 1997...

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • Nationwide Class Action Lawsuit--Phen/Fen and Primary Pulmonary Hypertension. Brous, Edie // Journal of Nursing Law;Spring2005, Vol. 10 Issue 1, p5 

    This article describes the origin of phen/fen combination use and its subsequent involvement in claims of primary pulmonary hypertension from a defense perspective. The national settlement criteria for inclusion in the subsequent class action suit is detailed, with descriptions of manipulative...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics